Evaluation of inactive Matrix-Gla-Protein (MGP) as a biomarker for incident and recurrent kidney stones

Abstract Background Matrix-Gla-protein (MGP) is an inhibitor of vascular calcification. Its dephosphorylated and uncarboxylated inactive form, dpucMGP, is a marker of vitamin K status and of cardio-vascular outcomes in chronic kidney disease. We hypothesized that higher serum dpucMGP would be a biomarker of kidney stone disease. Methods We measured serum dpucMGP in incident symptomatic kidney stone-formers and non-stone formers at a base- line visit. Symptomatic stone recurrence was assessed in the stones formers over a 5-year period. The association of dpuc- MGP with incident or recurrent kidney stones was assessed with and without adjustment for clinical, blood, and urine characteristics. Results There was no significant difference in serum dpucMGP level between 498 stone formers and 395 non-stone former (510 vs 501 pmol/L; p = 0.66). In a multivariable model adjusting for clinical, blood and urine chemistries, higher MGP was associated with lower risk of stone formation (OR = 0.674, 95% CI 0.522–0.870), contrary to previous reports. Among 375 stone formers with 5 years of follow-up, 79 (21%) had symptomatic recurrence. No difference in serum dpucMGP was evident in recurrent versus non-recurrent stone-formers (482 vs 502 pmol/L; p = 0.26). Serum dpucMGP was correlated with cystatin C levels in non stone-formers, incident stone-formers and recurrent stone-formers (r > 0.3, p < 0.0001). Conclusion Elevated serum dpucMGP was not associated with incident or recurrent symptomatic kidney stone events. How- ever, higher level of dpucMGP was associated with lower risk of kidney stone in a multivariable logistic regression model.